Immune-Mediated Necrotizing Myopathy (IMNM) is a rare and severe subtype of idiopathic inflammatory myopathy characterized by rapidly progressive proximal muscle weakness, markedly elevated serum creatine phosphokinase (CPK) levels, and muscle fibre necrosis with minimal inflammatory infiltrates. Statin exposure is a well-recognized trigger, although seronegative cases are increasingly reported.
Immune-mediated necrotizing myopathy, Statin-induced myopathy, HyperCKemia, Myoglobinuria, Inflammatory myopathy, Anti-HMGCR-negative myopathy
Immune-Mediated Necrotizing Myopathy (IMNM) is identified to have various etiologies. Among the various etiologies, statin-induced immune-mediated necrotizing myopathy has gained increasing recognition due to the widespread use of statins in cardiovascular disease prevention.
Unlike self-limiting toxic statin myopathy, IMNM persists even after discontinuation of statins because of an autoimmune process directed against muscle fibres. Patients often present with profound muscle weakness, myoglobinuria, dysphagia, and significantly elevated muscle enzymes. Early diagnosis and aggressive immunosuppressive therapy are essential to prevent morbidity and improve functional outcomes.
We report a case of acute inflammatory necrotizing myopathy, probably statin induced, in an elderly female who presented with severe proximal muscle weakness and markedly elevated CPK levels, with subsequent improvement following pulse methylprednisolone therapy.
A 69-year-old female with a known history of rheumatoid arthritis, systemic hypertension, seizure disorder, coronary artery disease status post single vessel PTCA and chronic statin use presented with progressive proximal muscle weakness involving both upper and lower limbs. The weakness was severe enough to impair ambulation and daily activities.
Initial evaluation revealed gross elevation of serum creatine phosphokinase (CPK) associated with myoglobinuria, suggestive of severe muscle injury. Clinical findings were consistent with an inflammatory myopathy. There was no evidence of active malignancy on evaluation with PET-CT, which demonstrated only low-grade muscle inflammation without evidence of neoplastic disease.
Myositis profile revealed weak positivity for PM-Scl antibodies, which was considered clinically insignificant. Anti-HMG-CoA reductase antibody testing was negative.
During the course of illness, the patient developed recent left lower limb proximal deep vein thrombosis with pulmonary embolism. ANA profile and antiphospholipid antibody screening were negative.
On examination during follow-up, the patient showed significant clinical improvement following treatment with pulse intravenous methylprednisolone. She became ambulatory with improvement in muscle symptoms. Residual proximal muscle power in bilateral upper and lower limbs was graded 3/5 initially, later progressing to normal muscle power on subsequent follow-up.
There was no active inflammatory joint pain at follow-up. A subtle facial rash was noted, though its clinical significance remained uncertain.
Based on the clinical presentation, markedly elevated CPK, proximal muscle weakness, myoglobinuria, exclusion of malignancy, and favorable response to corticosteroid therapy, a diagnosis of acute inflammatory necrotizing myopathy, probably statin induced, was made.
The differential diagnoses considered included toxic statin myopathy, polymyositis, dermatomyositis, rheumatoid arthritis-associated myositis, inclusion body myositis, viral myositis, and paraneoplastic necrotizing myopathy. The combination of severe proximal weakness, markedly elevated CPK, myoglobinuria, exclusion of malignancy, and favorable response to immunosuppressive therapy supported the diagnosis of probable statin-associated IMNM despite negative anti-HMGCR antibodies.
This overall clinicobiochemical profile strongly supports immune-mediated necrotizing myopathy, probably statin induced.
Management includes immediate cessation of statins and initiation of aggressive immunosuppressive therapy. High-dose corticosteroids remain first-line treatment, often combined with steroid-sparing agents or IVIG in refractory disease. Early treatment is associated with better functional recovery.
This patient demonstrated substantial clinical recovery following pulse methylprednisolone therapy, highlighting the importance of early recognition and treatment.
Acute inflammatory necrotizing myopathy is a rare but potentially disabling inflammatory muscle disease that should be considered in patients presenting with severe proximal muscle weakness and markedly elevated CPK levels, especially in the setting of statin exposure. Early diagnosis, exclusion of malignancy, and prompt immunosuppressive therapy are crucial for favorable outcomes.
This case emphasizes that statin-induced necrotizing myopathy may occur even in the absence of anti-HMGCR antibodies and can respond well to corticosteroid therapy.Top of Form
Zeel J. Patel; Lekha Racharla; Akhil Kher; Rahul Gupta; Andrew D. SumnerJACC (Journal of the American College of Cardiology), March 08, 2022, Volume 79, Issue 9, Pages 3181-3181
Dr. Sham S Senior Consultant Rheumatology, Kauvery Hospital, Chennai.
Dr. Roseline Sweety Jebapriya N DNB Resident Internal Medicine, Kauvery Hospital, Chennai.
